计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| V125454-10mg |
10mg |
现货 ![]() |
| |
| V125454-50mg |
50mg |
现货 ![]() |
| |
| V125454-1g |
1g |
现货 ![]() |
| |
| V125454-5g |
5g |
现货 ![]() |
| |
| V125454-10g |
10g |
现货 ![]() |
| |
| V125454-25g |
25g |
现货 ![]() |
| |
| V125454-100g |
100g |
现货 ![]() |
| |
| V125454-500g |
500g |
现货 ![]() |
|
| 别名 | 维达列汀 | 维他列汀 |
|---|---|
| 英文别名 | (2S)-1-{2-[(3-Hydroxyadamant-1-yl)amino]acetyl}pyrrolidine-2-carbonitrile | (2S)-{((3-Hydroxyadamantan-1-yl)amino)acetyl}pyrrolidine-2-carbonitrile | (2S)-1-{[(3-hydroxyadamant-1-yl)amino]acetyl}pyrrolidine-2-carbonitrile | Vildagliptin | NSC-37389 | s303 |
| 规格或纯度 | Moligand™, ≥99% |
| 英文名称 | Vildagliptin (LAF-237) |
| 生化机理 | 维达列汀(LAF-237)抑制 DPP?4,IC50 为 2.3 nM。 |
| 储存温度 | -20°C储存,充氩 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 二肽基肽酶 IV 抑制剂 |
| 产品介绍 |
Vildagliptin is a dipeptidyl peptidase-4 (CD26) inhibitor. CD26 activates serine proteases in immune/inflammatory cells. Vildagliptin also inhibits dipeptidyl-peptidase 8 (DPRP1) and dipeptidyl-peptidase 9 (DPRP2), which have been correlated to T cell activation and immune function, as well as diabetes and cancer regulation.A CD26 inhibitor associated with immune response inhibition Vildagliptin is a dipeptidyl peptidase-4 (CD26) inhibitor. CD26 activates serine proteases in immune/inflammatory cells. Vildagliptin also inhibits dipeptidyl-peptidase 8 (DPRP1) and dipeptidyl-peptidase 9 (DPRP2), which have been correlated to T cell activation and immune function, as well as diabetes and cancer regulation. |
| 纯度 | ≥99% |
| ALogP | 0.9 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 488195881 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | (2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile |
| INCHI | 1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1 |
| InChi Key | SYOKIDBDQMKNDQ-XWTIBIIYSA-N |
| Smiles | C1CC(N(C1)C(=O)CNC23CC4CC(C2)CC(C4)(C3)O)C#N |
| Isomeric SMILES | C1C[C@H](N(C1)C(=O)CNC23CC4CC(C2)CC(C4)(C3)O)C#N |
| PubChem CID | 6918537 |
| 分子量 | 303.4 |
| 溶解性 | Soluble in DMSO and Water |
|---|---|
| 敏感性 | 易吸潮 |
| 分子量 | 303.400 g/mol |
| XLogP3 | 0.900 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 4 |
| 可旋转键计数Rotatable Bond Count | 3 |
| 精确质量Exact Mass | 303.195 Da |
| 单同位素质量Monoisotopic Mass | 303.195 Da |
| 拓扑极表面积Topological Polar Surface Area | 76.400 Ų |
| 重原子数Heavy Atom Count | 22 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 523.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 1 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 2 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 危险声明 |
H413: 可能对水生生物造成长期的有害影响 |
|---|---|
| 预防措施声明 |
P273: 避免释放到环境中。 P501: 将内容物/容器处理到。。。 |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | V125454 | |
| 分析证书 | V125454 | |
| 分析证书 | V125454 | |
| 分析证书 | V125454 | |
| 分析证书 | V125454 | |
| 分析证书 | V125454 | |
| 分析证书 | V125454 | |
| 分析证书 | V125454 | |
| 分析证书 | V125454 | |
| 分析证书 | V125454 | |
| 分析证书 | V125454 | |
| 分析证书 | V125454 | |
| 分析证书 | V125454 | |
| 分析证书 | V125454 | |
| 分析证书 | V125454 | |
| 分析证书 | V125454 | |
| 分析证书 | V125454 | |
| 分析证书 | V125454 | |
| 分析证书 | V125454 | |
| 分析证书 | V125454 | |
| 分析证书 | V125454 |
| 1. Ma Jie, Li Huan, Hu Xiangnan, Yang Lu, Chen Qi, Hu Congli, Chen Zhihao, Tian Xiaoyan, Yang Yang, Luo Ying, Gan Run, Yang Junqing. (2017) CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies. Scientific Reports, 7 (1): (1-11). [PMID:28406239] [10.1038/srep46628] |
| 2. Wang Tianyan, Tao Ting, Liu Yi, Dong Jie, Ni Shanhong, Liu Yun, Li Yanli, Xu Ning, Sun Zengxian. (2024) Pharmacokinetic/Pharmacodynamic modelling of Saxagliptin and its active metabolite, 5-hydroxy Saxagliptin in rats with Type 2 Diabetes Mellitus. BMC Pharmacology & Toxicology, 25 (1): (1-15). [PMID:39103956] [10.1186/s40360-024-00757-3] |